YUCAIPA, Calif., March 29, 2011 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), an ISO 13485:2003 certified medical device manufacturer of respiratory medical devices, announced today that the company has received a Department of Veterans Affairs Federal Supply Scheduled Contract Award beginning on April 1, 2011 and ending on March 31, 2016.
On March 24, 2011 the company received a Contract Award Letter from the VA National Acquisition Center. The company was provided a copy of the Federal Supply Schedule Contract V797P-4379b, effective April 1, 2011 through March 31, 2016, for items awarded under 65IIA under the Medical Equipment and Supplies Federal Supply Schedule Solicitation 797-FSS-99-0025-R6.
"We submitted the 'GSA' application with the VA National Acquisition Center in September of 2009. With this contract award, we are able to sell our respiratory products to VA Hospitals and other government related medical facilities. Our new SMART Nasal Cannula which uses our Oxyview technology was introduced to the VA Hospitals last year through our strategic partnership with KGMA Business Solutions. Various government facilities expressed serious interest in the purchase of our respiratory products for their home care patients that are prescribed oxygen therapy," stated Gary Tilden, Chairman and COO.
About Ingen:
Our wholly owned subsidiary is an established ISO certified medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the US, and $8 billion globally. Visit www.ingen-tech.com.
The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.